Thyroid Eye Disease Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Market Overview:

The thyroid eye disease market reached a value of USD 2,255.8 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 4,458.8 Million by 2035, exhibiting a growth rate (CAGR) of 6.40% during 2025-2035.

The thyroid eye disease market has been comprehensively analyzed in IMARC's new report titled "Thyroid Eye Disease Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Thyroid eye disease, also known as Graves' ophthalmopathy or Graves' orbitopathy, is an autoimmune condition characterized by inflammation as well as swelling of the tissues around the eyes. It is primarily associated with an overactive thyroid gland (hyperthyroidism) caused by Graves' disease. However, the ailment can also occur in individuals suffering from normal thyroid function or even those with an underactive thyroid (hypothyroidism). It is characterized by a range of symptoms affecting the eyes and surrounding tissues, such as eye bulging (proptosis), eye pain, double vision (diplopia), dry eyes, redness and swelling of the eyelids, difficulty closing the eyes completely, changes in vision, etc. Diagnosing thyroid eye disease involves a comprehensive evaluation that typically consists of a detailed medical history, physical examination, assessment of eye symptoms, and specific diagnostic tests. Various clinical features, including eye bulging, eyelid retraction, double vision, eye redness, etc., are evaluated. Numerous imaging techniques, such as computed tomography (CT) and magnetic resonance imaging (MRI), may be used to visualize the orbital structures and detect inflammation or tissue changes. Additionally, several thyroid function tests, including measurement of thyroid hormone levels and thyroid antibody testing, help to support the disease diagnosis.

The rising cases of autoimmune disorders in which the immune system mistakenly targets the thyroid-stimulating hormone receptor on cells within the orbital tissues surrounding the eyes are primarily driving the thyroid eye disease market. In addition to this, the increasing prevalence of several associated risk factors, including hyperthyroidism, genetic predisposition, smoking, exposure to radiation or trauma, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of artificial tears and lubricating eye drops to alleviate dryness and provide temporary relief from discomfort is further augmenting the market growth. Additionally, the inflating utilization of orbital decompression surgery in cases where there is severe eye bulging or compression of the optic nerve is acting as another significant growth-inducing factor. This procedure involves removing some of the bone and fat around the eye socket to create more space for the swollen tissues. Furthermore, the escalating demand for strabismus surgery to help realign the eye muscles, restore normal vision, and reduce double vision is also bolstering the market growth. Besides this, the emerging popularity of orbital electromyography (EMG), since it aids in assessing muscle involvement and detecting muscle inflammation or fibrosis, is expected to drive the thyroid eye disease market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the thyroid eye disease market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for thyroid eye disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the thyroid eye disease market in any manner.

Recent Developments:

• In May 2025, Viridian Therapeutics stated that the United States FDA had granted Breakthrough Therapy Designation to veligrotug, the company’s lead anti-insulin-like growth factor-1 receptor (IGF-1R) drug candidate for the treatment of thyroid eye disease.
• In May 2025, Amgen disclosed that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) had granted marketing authorization for TEPEZZA (teprotumumab) as the first therapy specifically licensed for the treatment of adult patients with moderate-to-severe thyroid eye disease.
• In March 2025, HanAll Biopharma announced that Batoclimab had received Orphan Drug Designation (ODD) from the Ministry of Health, Labor and Welfare (MHLW) in Japan for active thyroid eye disease.
• In January 2025, ACELYRIN released additional Phase 2 data and the Phase 3 program design for lonigutamab in thyroid eye disease.
• In January 2025, Sling Therapeutics announced topline efficacy and safety data from the Phase 2b/3 LIDS trial of linsitinib in patients with active, moderate to severe thyroid eye disease.

Key Highlights:

• Thyroid eye disease is an autoimmune condition that affects 25-50% of persons who have Graves' disease.
• In the United States, the annual incidence of thyroid eye disease is 16 per 100,000 person-years in women and 3 per 100,000 person-years in men.
• This results in a 4:1 ratio of women to men with thyroid eye illness, owing to the higher incidence of hyperthyroidism among women. However, with severe thyroid eye illness, the female-to-male ratio flips to about 1:4.
• The estimated prevalence of this illness is 90 to 155 per 100,000 people in Europe and 100 to 300 per 100,000 people in Asia.
• Thyroid eye disease is more severe in older people who have a larger likelihood of restrictive myopathy and dysthyroid optic neuropathy.

Drugs:

Tepezza (teprotumumab) treats thyroid eye disease by targeting the root cause of the disease, which is the overactivity of the insulin-like growth factor-1 receptor (IGF-1R). It works by binding to and blocking IGF-1R, preventing it from stimulating orbital fibroblasts (cells behind the eye) that cause inflammation and tissue expansion. This ultimately reduces swelling, bulging, and other symptoms associated with thyroid eye disease.

VRDN 001, being developed by Viridian Therapeutics for thyroid eye disease, works by blocking the IGF-1R. This receptor is overactive in thyroid eye disease and contributes to the disease's symptoms by promoting inflammation and tissue swelling. By inhibiting IGF-1R, VRDN 001 aims to reduce these processes, potentially alleviating the signs and symptoms of the ailment, such as proptosis, diplopia, and pain.

Lonigutamab (VB421), a humanized monoclonal antibody, treats thyroid eye disease by targeting the IGF-1R. By binding to and inhibiting IGF-1R, lonigutamab reduces the signaling pathways that contribute to the inflammation and tissue expansion characteristic of thyroid eye disease. This mechanism differs from traditional treatments and may offer a more targeted approach.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the thyroid eye disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the thyroid eye disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current thyroid eye disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the thyroid eye disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the thyroid eye disease across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the thyroid eye disease across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of thyroid eye disease across the seven major markets?
• What is the number of prevalent cases (2019-2035) of thyroid eye disease by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of thyroid eye disease by gender across the seven major markets?
• What is the number of prevalent cases (2019-2035) of thyroid eye disease by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with thyroid eye disease across the seven major markets?
• What is the size of the thyroid eye disease patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend thyroid eye disease of?
• What will be the growth rate of patients across the seven major markets?

Thyroid Eye Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for thyroid eye disease drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the thyroid eye disease market?
• What are the key regulatory events related to the thyroid eye disease market?
• What is the structure of clinical trial landscape by status related to the thyroid eye disease market?
• What is the structure of clinical trial landscape by phase related to the thyroid eye disease market?
• What is the structure of clinical trial landscape by route of administration related to the thyroid eye disease market?